Qingdao Haier Biomedical Co Ltd (688139) — Capital Reinvestment Ratio

Latest as of June 2023: 7.36x

Qingdao Haier Biomedical Co Ltd (688139) has a Capital Reinvestment Ratio of 7.36x as of June 2023, meaning it reinvests 7% of its operating cash flow (CN¥7.33 Million) in capital expenditures (CN¥53.93 Million). See Qingdao Haier Biomedical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

7.36x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥7.33 Million
CNY

Capital Expenditures

CN¥53.93 Million
CNY

Data as of

Jun 2023
Most recent filing

Qingdao Haier Biomedical Co Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks Qingdao Haier Biomedical Co Ltd's Capital Reinvestment Ratio across 10 annual periods.

Annual Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for Qingdao Haier Biomedical Co Ltd from 2016 to 2025. For live market cap and broader valuation context, see Qingdao Haier Biomedical Co Ltd (688139) market capitalisation.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.45x CN¥267.89 Million CN¥119.25 Million ▲ +2.5%
2024 0.43x CN¥291.67 Million CN¥126.70 Million ▼ -38.9%
2023 0.71x CN¥249.26 Million CN¥177.18 Million ▲ +52.8%
2022 0.47x CN¥632.43 Million CN¥294.24 Million ▲ +43.8%
2021 0.32x CN¥632.43 Million CN¥204.69 Million ▲ +153.4%
2020 0.13x CN¥696.62 Million CN¥88.99 Million ▼ -78.7%
2019 0.60x CN¥280.49 Million CN¥168.40 Million ▲ +29.0%
2018 0.47x CN¥149.00 Million CN¥69.33 Million ▲ +155.8%
2017 0.18x CN¥148.32 Million CN¥26.98 Million ▲ +176.8%
2016 0.07x CN¥220.72 Million CN¥14.50 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow